Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2020
May 2020, Vol 10, No 5
May 2020, Vol 10, No 5
Wholesale Supply Channels: COVID-19 Impact on Cancer Care and Road to Recovery
AVBCC COVID-19 Webcast Series
,
COVID-19
During a recent Association for Value-Based Cancer Care (AVBCC) webcast, titled Wholesale Supply Channels: COVID-19 Impact on Cancer Care and Road to Recovery, a panel of healthcare experts discussed issues related to wholesale supply channels for the distribution of drugs and medical/surgical supplies to community oncology care providers.
Read Article ›
MicroRNAs Have Promise as Biomarker in Testicular and Other Germ-Cell Tumors
By
Wayne Kuznar
Biomarkers
MicroRNAs have all the characteristics to be a potential game changer as a biomarker in germ-cell tumors (originating in the testes, ovaries, and a few other sites), with high sensitivity, specificity, and clinical validity in pilot studies, said Lucia Nappi, MD, PhD, Medical Oncologist, British Columbia Cancer, Vancouver Centre, Canada, at the 2020 Genitourinary Cancers Symposium.
Read Article ›
NCCN Issues Guidance for Cancer Care During the COVID-19 Pandemic
By
Wayne Kuznar
COVID-19
The challenges of managing cancer during the COVID-19 pandemic raise new concerns for oncologists, nurses, and the entire cancer care team. The management of patients with cancer, who are at increased risk from this new respiratory infection, has rapidly become even more urgent.
Read Article ›
ASCO Publishes First Guideline on Use of Molecular Biomarkers in Localized Prostate Cancer
By
Rebecca Bailey
Biomarkers
The clinical course of prostate cancer is highly variable, reflecting the heterogeneity of the disease. Although most men diagnosed with prostate cancer have low-risk, favorable disease characteristics, some may harbor aggressive features and experience disease progression despite conventional therapy. Therefore, initial risk stratification is vitally important for determining effective treatment strategies and improving clinical outcomes.
Read Article ›
Adding 2 Immunotherapies to Cabozantinib Extends Survival in Advanced Liver Cancer
By
Wayne Kuznar
Immunotherapy
The addition of a second immunotherapy, ipilimumab (Yervoy), to the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) produced durable responses and longer progression-free survival (PFS) than cabozantinib plus nivolumab alone in patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. The overall survival (OS) was not yet reached in the triplet arm.
Read Article ›
Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer
By
Wayne Kuznar
Immunotherapy
The combination of atezolizumab (Tecentriq) immunotherapy plus bevacizumab (Avastin) improves survival as well as significantly delaying deterioration in quality of life compared with the current standard of the targeted therapy sorafenib (Nexavar) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read Article ›
SBRT plus Immunotherapy in Metastatic Renal-Cell Carcinoma Warrants
By
Phoebe Starr
Immunotherapy
Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium.
Read Article ›
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
By
Phoebe Starr
Emerging Therapies
Treatment with the novel agent MK-6482 led to promising results in a phase 1/2 clinical trial of patients with metastatic clear-cell renal-cell carcinoma (RCC). In heavily pretreated patients, the objective response rate (ORR) with single-agent MK-6482 was 24%, and a response was consistently seen across patients with favorable-, intermediate-, and poor-risk disease. These results were greeted with optimism at the 2020 Genitourinary Cancers Symposium.
Read Article ›
Combination of NUC-1031 plus Cisplatin Shows Promise as First-Line Treatment for Advanced Biliary Tract Cancer
By
Eileen Koutnik-Fotopoulos
Cholangiocarcinoma
Cholangiocarcinoma (CCA), a type of biliary tract cancer, is a rare malignancy, with no FDA-approved medications specifically for this type of cancer. The current standard first-line treatment for patients with locally advanced or metastatic CCA is a chemotherapy combination of gemcitabine and cisplatin.
Read Article ›
International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020
By
Meg Barbor, MPH
Medicinal Cannabis
Although medicinal cannabis has been used successfully as a palliative therapy in patients with cancer, it is still stigmatized because of its illicit scheduling. However, as research on cannabis use in oncology matures and the stigma begins to fall away, more states are allowing for pharmacist oversight of this product, and its legalization continues to spread.
Read Article ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes